Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.670
+0.030 (1.83%)
At close: Feb 13, 2026, 4:00 PM EST
1.650
-0.020 (-1.20%)
After-hours: Feb 13, 2026, 6:00 PM EST
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $228.43 million as of February 13, 2026. Its market cap has increased by 30.24% in one year.
Market Cap
228.43M
Enterprise Value
151.11M
1-Year Change
30.24%
Ranking
Category
Stock Price
$1.67
Market Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $228.43M, an increase of 127.39%. That is a compound annual growth rate of 17.31%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 13, 2026 | 228.43M | -18.54% |
| Dec 31, 2025 | 280.40M | -3.25% |
| Dec 31, 2024 | 289.83M | 3,596.14% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 23, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| OmniAb | 244.72M |
| Shattuck Labs | 244.26M |
| Coherus Oncology | 240.65M |
| Protalix BioTherapeutics | 238.85M |
| Nuvectis Pharma | 232.07M |
| Achieve Life Sciences | 223.58M |
| MediWound | 220.66M |
| Orchestra BioMed Holdings | 215.13M |